<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02543866</url>
  </required_header>
  <id_info>
    <org_study_id>15587</org_study_id>
    <nct_id>NCT02543866</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation as a Strategy to Eradicate Resistant Organisms</brief_title>
  <official_title>Fecal Microbiota Transplantation as a Strategy to Eradicate Intestinal Carriage of Resistant Organisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol will evaluate fecal microbiota transplantation (FMT) as a strategy to eradicate&#xD;
      intestinal colonization of extended-spectrum resistant (ESC-R) Enterobacteriaceae in&#xD;
      pediatric patients.&#xD;
&#xD;
      FMT will be performed on subjects with a history of at least one infection due to ESC-R&#xD;
      Enterobacteriaceae.&#xD;
&#xD;
      This protocol aims to determine the feasibility, safety, tolerability, and potential efficacy&#xD;
      of FMT in pediatric patients with a history of ESC-R Enterobacteriaceae.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective pilot study of fecal microbiota transplantation in pediatric patients&#xD;
      with a history of ESC-R Enterobacteriaceae. Subjects who meet inclusion/exclusion criteria&#xD;
      and provide written, informed consent will undergo screening studies and provide a pre-FMT&#xD;
      stool sample to confirm intestinal carriage of ESC-R Enterobacteriaceae. The FMT will be&#xD;
      administered by nasogastric tube in the outpatient setting by trained personnel. The subjects&#xD;
      will be monitored for potential adverse events, recurrence of MDRO infections, infections&#xD;
      that may be related to FMT, and worsening of existing comorbidities or development of new&#xD;
      comorbidities for the 12 months post-FMT with the option of participating in long-term&#xD;
      follow-up for up to 5 years post-FMT. Patients will provide stool samples 2 days, 2 weeks, 4&#xD;
      weeks, 8 weeks, 6 months, and 12 months post-FMT. These samples will be testing for ESC-R&#xD;
      Enterobacteriaceae.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of FMT as measured by Incidence, severity, and relatedness of solicited, unsolicited, and serious adverse events</measure>
    <time_frame>12 months post-FMT; optional long-tern follow-up for 5 years post-FMT</time_frame>
    <description>Incidence, severity, and relatedness of solicited, unsolicited, and serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of FMT</measure>
    <time_frame>2 days, 2 weeks, 4 weeks, 8 weeks, 6 months, 12 months post-FMT</time_frame>
    <description>Proportion of subjects free from ESC-R intestinal colonization and recurrent ESC-R infections 2 days, 2 weeks, 4 weeks, 8 weeks, 6 months, and 12 months post-FMT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Infection Resistant to Drugs</condition>
  <arm_group>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 50mL of prepared stool fecal via nasogastric tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>Fecal Microbiota Transplantation</description>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children and adolescents between 7 and 21 years of age.&#xD;
&#xD;
          2. A history at least one infection due to ESC-R Enterobacteriaceae. ESC-R isolates will&#xD;
             be defined as those non-susceptible to ceftriaxone, cefotaxime, or ceftazidime.&#xD;
&#xD;
          3. Parent/guardian and participant must be able to attend baseline and follow-up study&#xD;
             visits.&#xD;
&#xD;
          4. Subject must be willing and able to provide written informed consent or assent (as&#xD;
             appropriate by age).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any history of malignancy or any immunocompromised state (e.g. absolute&#xD;
             neutrophil count outside the normal range) induced by disease or therapy will be&#xD;
             excluded.&#xD;
&#xD;
          2. Patients with past or current use of systemic immunosuppressive agents will be&#xD;
             excluded. Receipt of non-systemic agents such as inhaled, nasal, or topical steroids&#xD;
             or immune-modulating agents are allowed.&#xD;
&#xD;
          3. Lack of intestinal carriage of ESC-R Enterobacteriaceae (negative selective stool&#xD;
             culture for ESC-R Enterobacteriaceae).&#xD;
&#xD;
          4. Allergy or hypersensitivity to omeprazole and polyethylene glycol.&#xD;
&#xD;
          5. Pregnancy.&#xD;
&#xD;
          6. Current history of frequent (&gt;1 per week) vomiting.&#xD;
&#xD;
          7. Active inflammatory gastrointestinal disease, such as inflammatory bowel disease&#xD;
&#xD;
          8. Active mucositis or acute graft versus host disease of the gastrointestinal tract&#xD;
&#xD;
          9. Concurrent abdominal radiation therapy.&#xD;
&#xD;
         10. Inability to tolerate nasogastric tube placement or contraindication to having an NG&#xD;
             tube placed.&#xD;
&#xD;
         11. Presence of a ventriculoperitoneal shunt or other intrabdominal device, receipt of&#xD;
             renal dialysis, presence of ascites, or other conditions/devices that would increase&#xD;
             the risk of peritonitis.&#xD;
&#xD;
         12. Bleeding diatheses&#xD;
&#xD;
         13. Patients with current active ESC-R Enterobacteriaceae infection who have not yet&#xD;
             completed antibiotic treatment will be excluded until their treatment is completed&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danielle Zerr, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Adler</last_name>
    <phone>206-884-5086</phone>
    <email>amanda.adler@seattlechildrens.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle M Zerr, MD, MPH</last_name>
      <phone>206-987-2653</phone>
      <email>danielle.zerr@seattlechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Adler, BA</last_name>
      <phone>206-884-5086</phone>
      <email>amanda.adler@seattlechildrens.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 4, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Danielle Zerr</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

